William Cooper
Pulmonary Disease · Virginia Beach, VANPI 1124127147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AstraZeneca at 26.8% of the total. Reporting peaked in 2019 at $1,240 and has fallen 88.8% since, to $139 in 2022. That places this record below the midpoint for pulmonary disease clinicians in VA, where the typical reported total is $1,962.
Across 78 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$403
- Zimmer Biomet$139
- Genentech USA, Inc.$138
- Mallinckrodt Enterprises LLC$124
- GSK$114
- Sunovion Pharmaceuticals Inc.$102
- plus $480 from 19 others
What the payments were for
- Food & beverage$1,46497%
- Education$383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $403 |
| Zimmer Biomet | 1 | $139 |
| Genentech USA, Inc. | 7 | $138 |
| Mallinckrodt Enterprises LLC | 8 | $124 |
| GSK | 8 | $114 |
| Sunovion Pharmaceuticals Inc. | 6 | $102 |
| Advanced Respiratory, Inc | 4 | $66 |
| Boehringer Ingelheim | 2 | $50 |
| Pfizer | 3 | $43 |
| Philips North America LLC | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Mylan Specialty L.p. | 2 | $23 |
| Novartis | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Resmed Corp | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Bayer | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
| Insmed, Inc. | 1 | $11 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- mymobility Platform$139
- FASENRA$125
How this compares
$1,502 in reported general payments places this provider in the 45th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Virginia Beach
- Vasantha HathwarVirginia Beach$13K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
- Ellen VolkerCharlottesville$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.